Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ...

- Change in plasma pyrophosphate (PPi) as primary endpoint in the U.S. and co-primary endpoint in the EU for planned ENERGY-3 pivotal trial in pediatric patients -

Related Keywords

United States ,Boston ,Massachusetts ,Douglasa Treco ,Matt Pera ,Inozyme Pharma ,Stefan Riley ,Nasdaq ,Exchange Commission ,Drug Administration ,Facebook ,Corporate Communications ,European Medicines Agency ,Inozyme Pharma Inc ,Linkedin ,Twitter ,Paediatric Committee ,Planned Pivotal Trial ,Pediatric Patients ,Primary Endpoints ,Radiographic Global Impression ,Investor Relations ,Private Securities Litigation Reform Act ,Annual Report ,Region ,